Current members

Conflicts of Interest
Banovic, Frane
University of Georgia, Athens, Georgia
Boeringer Ingelheim (1,2) Vetoquinol (2), Ceva (1,2)
Bensignor, Emmanuel
DrVet, Dipl ECVD
Veterinary Dermatology and Allergology Referrals, Rennes/Nantes/Paris,France
Bayer (1, 2) ii. Virbac (1, 2) iii. Novartis (1, 2) iv. Elanco (1, 2) v. Royal Canin (1, 2) vi. Laboratoire de Dermo-Cosmetique Animale (LDCA; 1, 2) vii. CEVA (1, 2) viii. Laboratoire Destaing (1, 2) ix. ICF pet (1, 2) x. Zoetis (1, 2)
DeBoer, Douglas
University of Wisconsin, Madison, Wisconsin, USA
Bayer (1) ii. Zoetis (1, 2) iii. Elanco (1) iv. Heska (1, 2) v. Delmont laboratories (2, 5) vi. Kindred Biosciences (1, 3)
Eisenschenk, Melissa
Pet Dermatology Clinic, Maple Grove, Minnesota, USA
Zoetis (1)
Griffin, Craig
Animal Dermatology Clinics, San Diego, California, USA
Boehringer Ingelheim (1) ii. Elanco (1, 2, 4) iii. Purina (1, 2) iv. Merck (1, 4) v. VetBiotek (1, 4) vi. Veterinary Allergy Reference Laboratory (1, 7) vii. Zoetis (1, 4)
Hensel, Patrick
DrMedVet, Dipl ECVD, Dipl ACVD
Tierdermatologie Basel, Münchenstein, Switzerland
Purina (2)
Jackson, Hillary
The Dermatology Referral Service, Glasgow, Scotland, UK
Greer (1) ii. Royal Canin (1)
Mueller, Ralf
DrMedVet,DrHabil, FANZCVSc, Dipl ACVD, Dipl ECVD
Ludwig-Maximilian University, Munich, Germany
i. Novartis (1, 2) ii. Zoetis (1, 3) iii. Bayer (1) iv. Virbac (1, 2, 3) v. Selectavet (1) vi. Synlab (1) vii. Royal Canin (1, 2) viii. Elanco (1, 3) ix. LCDA (1, 2)
Nuttall, Tim
BSc, BVSc, CertVD, PhD, CBiol, MSB, MRCVS
The Royal (Dick) School of Veterinary Studies, Easter Bush Campus, Midlothian, UK
Ceva Animal Health (1,2) ii. Avacta Animal Health (1,2,3) iii. Dechra Animal Health (3) iv. Elanco Animal Health (2,3) v. Zoetis (1,2,3) vi. Simini Technologies (3) vii. Norbrook Laboratories (1) viii. Virbac Animal Health (1,2) ix. Royal Canin (1,2)
Prost, Christine
Sanofi, Lyon, France
i. Sanofi (6)
Pucheu-Haston, Cherie
Louisiana State University, Baton Rouge, Louisiana, USA
Royal Canin (2) • Virox Animal Health (2) • Kinetic Vet (1)
Santoro, Domenico
DVM, MS, PhD, DrSc, Dipl ACVD, Dipl ECVD, Dipl ACVM
University of Florida, Gainesville, Florida, USA
i. Virbac (1)
Saridomichelakis, Manolis
University of Thessaly, Karditsa, Greece
i. Bayer (1) ii. Elanco (1,2) iii. Hill’s (1,2) iv. ICF (2) v. Merial (1) vi. MSD (1) vii. Royal Canin (1) viii. Virbac (1,2) ix. Zoetis (1)

Conflict of interest key: 1 = received consulting or lecturing fees from company  2 = received research, teaching, or travel support funds from company  3 = on advisory board/board of directors of company  4 = have ownership interest in company  5 = have intellectual property relationship with company  6 = company employee  7 = other conflict

Conflict of interest policy

ICADA recognizes that its membership consists of a community of experts, and as such, its members periodically may engage in commercial and/or financial activities related to the field of veterinary allergy. Such activities may include (but are not limited to) employment by a commercial company that sells products or services related to allergy; performing consultation, lecturing, or advisory services for such a company; receiving research or educational grant support from such a company; or possessing an ownership or financial interest in a company, its intellectual property, or its products. ICADA recognizes that such relationships are most often minor and of insubstantial consequence. However, they may at times constitute, or be viewed by the public as constituting, a conflict of interest (COI).

ICADA is committed to recognizing and managing COIs within its membership through adherence to the following principles:

  • Disclosure: each ICADA member shall disclose all commercial relationships, as above, and update such disclosure at least once annually.

  • Transparency: commercial relationships of all ICADA members shall be listed for public viewing on the ICADA website.

  • Review: prior to engaging in any ICADA activity, such as serving on a subcommittee or study group, authoring an ICADA-sanctioned review or manuscript, etc., members shall discuss with and seek advice from the group as a whole as to whether their commercial relationship constitutes a substantial COI, and if it does, the member may either refrain from the activity or seek advice regarding management of the COI.

  • Management: in the event that the group finds that a substantial COI exists (or could be perceived to exist) but can be managed, a brief but specific written management plan must be submitted to the group and will become part of the annual meeting minutes. Examples of management steps that may be considered would include recusal from specific group discussions or abstention from specific votes, restriction from authorship or review of certain group-authored manuscripts, or appointment of another individual to perform tasks that could not reasonably be done without contributing to the COI.


Membership policies​

Interested in joining us?  Click HERE to open membership policies document.